Carbylan Therapeutics, Inc. (Carbylan Therapeutics) is a clinical-stage specialty pharmaceutical company. The Company is focused on the development and commercialization of combination therapies that address unmet medical needs. The Company’s focus is on the development of Hydros-TA, an intra-articular (IA), injectable product candidate to treat pain associated with osteoarthritis (OA), of the knee. Hydros-TA utilizes cross-linking technology to deliver both rapid pain relief with a low dose corticosteroid triamcinolone acetonide, (TA), and sustained pain relief from hyaluronic acid viscosupplement. It is comprised of bacterially-derived HA-based hydrogel particles suspended in a solution of hyaluronic acid. Hydros-TA is being studied in its COR1.1 trial, a Phase III, multi-center, randomized, double-blind, three-arm trial with grade two and grade three OA of the knee.